Gold Samuel A, Sabarwal Vikram K, Gordhan Chirag, Hale Graham R, Winer Andrew
SUNY Downstate College of Medicine, Downstate Medical Center, Brooklyn, NY, USA.
Department of Urology, George Washington University Hospital, Washington, DC, USA.
Transl Androl Urol. 2018 Oct;7(5):774-782. doi: 10.21037/tau.2018.07.21.
Pediatric renal and suprarenal cancers are relatively rare malignancies, but are not without significant consequence to both the patient and caretakers. These tumors are often found incidentally and present as large abdominal masses. Standard of care management involves surgical excision of the mass, but contemporary treatment guidelines advocate for use of neoadjuvant or adjuvant chemotherapy for advanced stage disease, such as those cases with lymph node involvement (LNI). However, LNI detection is based primarily on surgical pathology and performing extended lymph node dissection can add significant morbidity to a surgical case. In this review, we focus on the use and performance of imaging modalities to detect LNI in Wilms' tumor (WT), neuroblastoma, and pediatric renal cell carcinoma (RCC). We report on how imaging impacts management of these cases and the clinical implications of LNI. A literature search was conducted for studies published on imaging-based detection of LNI in pediatric renal and suprarenal cancers. Further review focused on surgical and medical management of those cases with suspected LNI. Current imaging protocols assisting in diagnosis and staging of pediatric renal and suprarenal cancers are generally limited to abdominal ultrasound and cross-sectional imaging, mainly computed tomography (CT). Recent research has investigated the role of more advance modalities, such as magnetic resonance imaging (MRI) and positron emission tomography (PET), in the management of these malignancies. Special consideration must be made for pediatric patients who are more vulnerable to ionizing radiation and have characteristic imaging features different from adult controls. Management of pediatric renal and suprarenal cancers is influenced by LNI, but the rarity of these conditions has limited the volume of clinical research regarding imaging-based staging. As such, standardized criteria for LNI on imaging are lacking. Nevertheless, advanced imaging modalities are being investigated and potentially represent more accurate and safer options.
小儿肾和肾上腺癌症是相对罕见的恶性肿瘤,但对患者及其护理人员来说都有着重大影响。这些肿瘤常常是偶然发现的,表现为腹部的巨大肿块。标准的治疗管理包括手术切除肿块,但当代治疗指南主张对晚期疾病,如那些有淋巴结受累(LNI)的病例,使用新辅助或辅助化疗。然而,LNI的检测主要基于手术病理学,而进行扩大的淋巴结清扫会给手术病例增加显著的发病率。在本综述中,我们重点关注成像模态在检测肾母细胞瘤(WT)、神经母细胞瘤和小儿肾细胞癌(RCC)中LNI的应用和表现。我们报告成像如何影响这些病例的管理以及LNI的临床意义。我们对已发表的关于小儿肾和肾上腺癌症基于成像检测LNI的研究进行了文献检索。进一步的综述聚焦于那些疑似LNI病例的手术和药物治疗。目前协助小儿肾和肾上腺癌症诊断及分期的成像方案通常仅限于腹部超声和断层成像,主要是计算机断层扫描(CT)。最近的研究探讨了更先进的模态,如磁共振成像(MRI)和正电子发射断层扫描(PET),在这些恶性肿瘤管理中的作用。对于更容易受到电离辐射影响且具有与成人对照不同的特征性成像表现的小儿患者,必须给予特殊考虑。小儿肾和肾上腺癌症的管理受LNI影响,但这些病症的罕见性限制了基于成像分期的临床研究数量。因此,缺乏成像上LNI的标准化标准。尽管如此,先进的成像模态正在被研究,并且可能代表更准确和更安全的选择。